IN8bio, Inc.
INABNASDAQHealthcareBiotechnology
Previous close
$1.28
+$0.07 · +5.79%
Pre-market
$1.22
−$0.06 · -4.69%
Aug 24, 4:00 AM ET
INAB company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
48
Fair Value
Momentum
30
Weakening
Sentiment
41
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteIN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- William T.
- Listed since
- Jul 30, 2021
- Employees
- 18
Market position
Day range
Current $1.28
52-week range
Current $1.28
- Open
- $1.23
- Previous close
- $1.21
- Volume
- 105.89K
- 1.69× average
- Average volume
- 62.82K
- Average daily volume
- Market cap
- 12.27M USD
- Beta
- 0.28
- Market reference 1
- 50-day average
- $1.2572
- +1.82% above average
- 200-day average
- $1.6279
- -21.37% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -0.68×
- P/B (TTM)
- 1.36×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0.12×
Earnings
- EPS beat rate
- 36%
- 4 beats, 7 misses, 0 met estimates
- Average EPS surprise
- -440.72%
- 11 comparable reports
- Latest EPS result
- -0.25
- Estimate -0.34 · Beat by 27.26%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$4.00
212.50% upsideINAB news
INAB peers
ETFs holding INAB
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research INABresearch.disclaimer